Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation
© 2024 British Society for Haematology and John Wiley & Sons Ltd..
The second revision of the International Staging System (R2-ISS) is a simple tool to risk-stratify newly diagnosed multiple myeloma (NDMM) patients. Here, we completed a retrospective analysis to evaluate the utility of R2-ISS in NDMM patients who underwent up-front autologous haematopoietic stem cell transplantation (auto-HCT). A total of 1291 patients were included, with a median age of 62 years (range 29-83). The distribution of R2-ISS stages was: 123 (10%) stage I, 471 (36%) stage II, 566 (44%) stage III and 131 (10%) stage IV. With a median follow-up of 42.2 months (range 0.3-181.0), the median PFS was 73.0, 65.2, 44.0 and 24.8 months, (p < 0.001) and the median OS was 130.8, 128.5, 94.2 and 61.4 months (p < 0.001) for patients with R2-ISS stages I, II, III and IV respectively. On multivariable analysis (MVA) for PFS, using R2-ISS stage I as reference, R2-ISS stages III (hazard ratio [95% confidence interval], 1.55 [1.05-2.29]; p = 0.028) and IV (2.04 [1.24-3.36]; p = 0.005) were associated with significantly inferior PFS. In the MVA of OS, using R2-ISS stage I as reference, only R2-ISS stage IV was associated with significantly inferior OS (2.43 [1.18-5.01]; p = 0.017). Overall, we found that R2-ISS is a reliable prognostic tool for NDMM patients undergoing up-front auto-HCT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
British journal of haematology - (2024) vom: 06. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alzahrani, Kamal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Haematopoietic stem cell transplantation |
|---|
| Anmerkungen: |
Date Revised 26.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1111/bjh.19384 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369377788 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369377788 | ||
| 003 | DE-627 | ||
| 005 | 20240326235727.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240307s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.19384 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1349.xml |
| 035 | |a (DE-627)NLM369377788 | ||
| 035 | |a (NLM)38448009 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alzahrani, Kamal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a The second revision of the International Staging System (R2-ISS) is a simple tool to risk-stratify newly diagnosed multiple myeloma (NDMM) patients. Here, we completed a retrospective analysis to evaluate the utility of R2-ISS in NDMM patients who underwent up-front autologous haematopoietic stem cell transplantation (auto-HCT). A total of 1291 patients were included, with a median age of 62 years (range 29-83). The distribution of R2-ISS stages was: 123 (10%) stage I, 471 (36%) stage II, 566 (44%) stage III and 131 (10%) stage IV. With a median follow-up of 42.2 months (range 0.3-181.0), the median PFS was 73.0, 65.2, 44.0 and 24.8 months, (p < 0.001) and the median OS was 130.8, 128.5, 94.2 and 61.4 months (p < 0.001) for patients with R2-ISS stages I, II, III and IV respectively. On multivariable analysis (MVA) for PFS, using R2-ISS stage I as reference, R2-ISS stages III (hazard ratio [95% confidence interval], 1.55 [1.05-2.29]; p = 0.028) and IV (2.04 [1.24-3.36]; p = 0.005) were associated with significantly inferior PFS. In the MVA of OS, using R2-ISS stage I as reference, only R2-ISS stage IV was associated with significantly inferior OS (2.43 [1.18-5.01]; p = 0.017). Overall, we found that R2-ISS is a reliable prognostic tool for NDMM patients undergoing up-front auto-HCT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a International Staging System | |
| 650 | 4 | |a R2-ISS | |
| 650 | 4 | |a haematopoietic stem cell transplantation | |
| 650 | 4 | |a multiple myeloma | |
| 700 | 1 | |a Pasvolsky, Oren |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhongya |e verfasserin |4 aut | |
| 700 | 1 | |a Milton, Denái R |e verfasserin |4 aut | |
| 700 | 1 | |a Tanner, Mark R |e verfasserin |4 aut | |
| 700 | 1 | |a Bashir, Qaiser |e verfasserin |4 aut | |
| 700 | 1 | |a Srour, Samer |e verfasserin |4 aut | |
| 700 | 1 | |a Saini, Neeraj |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Ramdial, Jeremy |e verfasserin |4 aut | |
| 700 | 1 | |a Nieto, Yago |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Hans C |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Krina K |e verfasserin |4 aut | |
| 700 | 1 | |a Manasanch, Elisabet E |e verfasserin |4 aut | |
| 700 | 1 | |a Kebriaei, Partow |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Sheeba K |e verfasserin |4 aut | |
| 700 | 1 | |a Weber, Donna M |e verfasserin |4 aut | |
| 700 | 1 | |a Orlowski, Robert Z |e verfasserin |4 aut | |
| 700 | 1 | |a Shpall, Elizabeth J |e verfasserin |4 aut | |
| 700 | 1 | |a Champlin, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Qazilbash, Muzaffar H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g (2024) vom: 06. März |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:06 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.19384 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 06 |c 03 | ||